Polypharmacy of osteoarthritis: The perfect intestinal storm

Digestive Diseases and Sciences

Volumn 58, Issue 11, 2013, Pages 3088-3093

  Wallace, John L ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Arthritis; Enteropathy; Gastric acid; Nonsteroidal anti inflammatory drugs; Proton pump inhibitors; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; FAMOTIDINE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE; ROFECOXIB;

DIGESTIVE SYSTEM INJURY; DISEASE EXACERBATION; ENTEROPATHY; HEART PROTECTION; HUMAN; INTESTINE INJURY; LOW DRUG DOSE; MORBIDITY; OSTEOARTHRITIS; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; STOMACH HEMORRHAGE; STOMACH ULCER; THROMBOCYTE AGGREGATION;

AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS; OSTEOARTHRITIS; POLYPHARMACY;

EID: 84889578648     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2777-8     Document Type: Review

References (45)

1. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheumatol Dis Clin N Am. 2013;39:1-19.
2. Hochber MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip and knee. Arthritis Care Res. 2012;64:465-474.
3. Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481-496.
4. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-1322.
5. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633-1641.
6. Zhao Y, Encinosa W. Hospitalizations for Gastrointestinal Bleeding in 1998 and 2006: Statistical Brief #65. Health Care Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Health Care Policy and Research; 2008.
7. Satoh H, Amagase K, Takeuchi K. Exacerbation of NSAID-induced small intestinal lesions by anti-secretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther. 2012;343:270-277.
8. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006;82:186-191.
9. Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med. 2004;117:8-13.
10. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302-1308.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
12. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247-1255.
13. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low dose enteric-coated aspirin and the effect of COX-2-selective inhibition: a double-blind trial. Gastroenterology. 2003;127:395-402.
14. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci. 1999;20:4-6.
15. Bjarnason I, Zanelli G, Smith T, et al. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol. 1987;64:55-62.
16. McCarthy DM. GI bleeding: problems that persist. Gastrointest Endosc. 2009;7:225-228.
17. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule endoscopy study. Clin Gastroenterol Hepatol. 2007;5:1040-1045.
18. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med. 1998;338:719-726.
19. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med. 2004;117:72S-78S.
20. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding/perforation. Gastroenterology. 1992;103:8629-8637.
21. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002;16:497-506.
22. Casado Arroyo RC, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718-723.
23. Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci. 1999;2:5-14.
24. Endo H, Sakai E, Higurashi T, et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44:833-838.
25. Grosser T, Fries S, Lawson LA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377-385.
26. Wallace JL. Prostaglandins, NSAIDs and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev. 2008;88:1547-1565.
27. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012;165:67-74.
28. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19:1861-1876.
29. Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455-460.
30. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3-10.
31. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504-508.
32. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI on producing bowel symptoms and SIBO. Eur Clin Invest. 2011;41:380-386.
33. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573-574.
34. Andreasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med. 2011;270:50-57.
35. Desilets AR, Asal NJ, Dunican KC. Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm. 2012;27:114-120.
36. Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol. 2009;43:551-553.
37. Keszthelyl D, Jansen SV, Schouten GA. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32:1124-1128.
38. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology. 2011;140:1155-1165.
39. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56:2349-2353.
40. Watanabe T, Tanigawa T, Nadatani Y, et al. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis. 2013;45:390-395.
41. Sakai E, Endo H, Taniguchi L, et al. Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding. Dig Endosc. 2012;25:412-420. doi: 10.1111/den.12002.
42. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. Microbiol Immunol. 1996;40:553-560.
43. Kinouchi T, Kataoka K, Bing SR, et al. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Micriobiol Immunol. 1998;42:347-355.
44. Syer SD, McKnight W, Aucouturier A, et al. Bifidobacteria exert a protective effect against NSAID-induced enteropathy that is dependent on lactate production. Gastroenterology. 2012;142:S-489 (abstract).
45. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506-G513.